NCI / Bioclinica Inc / Melblez Kit Delcath Systems Inc. / /
Event
FDA Phase / Business Partnership / /
Facility
University of Pittsburgh Medical Center / National Cancer Institute / John Wayne Cancer Institute / /
IndustryTerm
nonNCI site / treatment of hepatic tumors secondary to melanoma / cancer treatment / parallel / treatment of patients with metastatic melanoma / melanoma site / drug/device combination product / treatment of patients with unresectable or metastatic melanoma / tumor site / treatment of metastatic or unresectable melanoma / treatment of patients with cutaneous melanoma / treatment of melanoma / patient management / healthcare providers prescribing / combination product / treatment of patients with unresectable metastatic ocular melanoma / investigational site / melanoma prior site / treatment of metastatic cancer / healthcare providers / therapies for metastatic ocular melanoma / /
National Cancer Institute / FDA Briefing Document Oncologic Drugs Advisory Committee / Food and Drug Administration / FDA’s office of Combination Products / American Society of Clinical Oncology / University of Pittsburgh / Review Division / Oncologic Drugs Advisory Committee / Center for Drug Evaluation and Research / Advisory Committee / Pittsburgh Medical Center / John Wayne Cancer Institute / /
Person
Van Raamsdonk / /
Position
investigator / referring physician / treating physician / Major / medical officer / /